|
S1133
|
MLN8237 (Alisertib) |
MLN8237 (Alisertib) is a selective Aurora A inhibitor with IC50 of 1.2 nM. |
|
|
|
S1147
|
Barasertib (AZD1152-HQPA) |
AZD1152-HQPA (Barasertib) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM. |
|
|
|
S1048
|
VX-680 (MK-0457, Tozasertib) |
VX-680 (MK-0457, Tozasertib) is a pan-Aurora inhibitor of Aurora A, Aurora B and Aurora C with Kiapp of 0.6 nM, 18 nM and 4.6 nM, respectively. |
|
|
|
S1107
|
Danusertib (PHA-739358) |
Danusertib (PHA-739358) is an Aurora inhibitor for Aurora A/B/C, Bcr-Abl, c-RET and FGFR with IC50 of 13 nM/79 nM/61 nM, 25 nM, 31 nM and 47 nM, respectively. |
|
|
|
S1103
|
ZM-447439 |
ZM-447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. |
|
|
|
S4910
|
ABT-348 (Ilorasertib) |
ABT-348 is a novel ATP-competitive inhibitor of Aurora B, Aurora C and Aurora A with IC50 of 7 nM, 1 nM and 120 nM, respectively. |
|
|
|
S2018
|
ENMD-2076 L-(+)-Tartaric acid |
ENMD-2076 L-(+)-Tartaric acid is the tartaric acid of ENMD-2076, a selective inhibitor of Aurora A and Aurora B with IC50 of 14 nM and 350 nM and also inhibits Flt3, Flt4 and VEGFR2 with IC50 of 1.86 nM, 15.9 nM and 58.2 nM, respectively. |
|
|
|
S1249
|
JNJ-7706621 |
JNJ-7706621 is a potent and multi-target inhibitor for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, Aurora A and Aurora B with IC50 of 9 nM, 4 nM, 3 nM, 11 nM and 15 nM, respectively. |
|
|
|
S1100
|
MLN8054 |
MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM. |
|
|
|
S1134
|
AT9283 |
AT9283 is a potent pan-Aurora inhibitor for Aurora A, Aurora B, JAK3, JAK2 and Abl with IC50 of 3 nM, 3 nM, 1.1 nM, 1.2 nM and 4 nM, respectively. |
|
|